Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/46570
Authors: 
Grossmann, Volker
Year of Publication: 
2011
Series/Report no.: 
CESifo working paper: Public Finance 3439
Abstract: 
This paper examines the role of both cost-sharing schemes in health insurance systems and entry regulation for pharmaceutical R&D expenditure, drug prices, aggregate productivity, and income. The analysis suggests that both an increase in the coinsurance rate and stricter price regulations adversely affect R&D spending in the pharmaceutical sector. In contrast, entry deregulation may lead to quality-improvements of pharmaceuticals, despite reducing price-setting power of pharmaceutical companies. Extension to an endogenous growth context suggests that, when individual labor supply depends on health status, both cost-sharing and entry barriers in the pharmaceutical sector also affect aggregate productivity and wage rates.
Subjects: 
aggregate productivity
cost-sharing
entry deregulation
health insurance
pharmaceutical innovation
JEL: 
I10
L10
O30
Document Type: 
Working Paper

Files in This Item:
File
Size
466.41 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.